Eva Domingo‐Doménech

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

Medicine, Hematology, Oncology +12

Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients

Carlota Gudiol, Marta Bodro, Antonella F. Simonetti et al. · Clinical Microbiology and Infection · 2012 · 304 citations · Full text

Life Sciences, Microbiology, Oncology +17

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · Annals of Oncology · 2021 · 262 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study

Radhakrishnan Ramchandren, Eva Domingo‐Doménech, Antonio Rueda et al. · Journal of Clinical Oncology · 2019 · 256 citations · Full text

Medicine, Oncology, Pharmacology +17

Inappropriate Empirical Antibiotic Treatment in High-risk Neutropenic Patients With Bacteremia in the Era of Multidrug Resistance

Gemma Martínez‐Nadal, Pedro Puerta‐Alcalde, Carlota Gudiol et al. · Clinical Infectious Diseases · 2019 · 164 citations

Pharmacy, Infectious Diseases, Microbiology +16